Syndya Therapeutics

Executive Summary

Syndya Therapeutics is a Swiss biotechnology company in stealth mode, founded in 2019, developing small molecule therapeutics for metabolic and inflammatory diseases. The company's proprietary 3D combinatorial phenotypic screening platform targets protein-protein interactions, with initial focus on metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Syndya plans to emerge from stealth in early 2025, at which point it will disclose additional details on its platform, pipeline, and development strategy. Given the early stage and lack of public data, the company's progress remains speculative, but its innovative approach and management's experience in Basel's biotech hub suggest potential for future breakthroughs. The company has not disclosed funding or valuation.

Upcoming Catalysts (preview)

• Q1 2025Emergence from stealth mode and public disclosure of platform/pipeline80% success
• Q2 2025Release of preclinical proof-of-concept data for lead MASH program50% success
• Q3 2025First partnership or collaboration deal leveraging 3D screening platform40% success